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Abstract 74 
Background: Genome-wide association studies have identified multiple loci associated with 75 
stroke. However, the specific stroke subtypes affected, and whether loci influence both 76 
ischaemic and haemorrhagic stroke, remains unknown. For loci associated with stroke, we 77 
aimed to infer the combination of stroke subtypes likely to be affected, and in doing so assess 78 
the extent to which such loci have homogeneous effects across stroke subtypes. 79 
Methods: We performed Bayesian multinomial regression in 16,664 stroke cases and 32,792 80 
controls of European ancestry to determine the most likely combination of stroke subtypes 81 
affected for loci with published genome-wide stroke associations, using model selection. 82 
Cases were subtyped under two commonly used stroke classification systems, Trial of Org 83 
10172 Acute Stroke Treatment (TOAST) and Causative Classification of Stroke (CCS). All 84 
individuals had genotypes imputed to the Haplotype Reference Consortium 1.1 Panel. 85 
Results: Sixteen loci were considered for analysis. Seven loci influenced both haemorrhagic 86 
and ischaemic stroke, three of which influenced ischaemic and haemorrhagic subtypes under 87 
both TOAST and CCS. Under CCS, 4 loci influenced both small vessel stroke and 88 
intracerebral haemorrhage. An EDNRA locus demonstrated opposing effects on ischaemic 89 
and haemorrhagic stroke. No loci were predicted to influence all stroke subtypes in the same 90 
direction and only one locus (12q24) was predicted to influence all ischaemic stroke subtypes. 91 
Conclusions: Heterogeneity in the influence of stroke-associated loci on stroke subtypes is 92 
pervasive, reflecting differing causal pathways. However, overlap exists between 93 
haemorrhagic and ischaemic stroke, which may reflect shared pathobiology predisposing to 94 
small vessel arteriopathy. Stroke is a complex, heterogeneous disorder requiring tailored 95 
analytic strategies to decipher genetic mechanisms.  96 
Keywords: Stroke, Multinomial, EDNRA, Genetics, intracerebral haemorrhage  97 
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Introduction 98 
The burden of stroke on global healthcare and society is substantial; it is consistently one of 99 
the leading causes of death and disability worldwide, 1 and a major cause of cognitive 100 
impairment and dementia. However, there exist significant gaps in our understanding of the 101 
pathological processes that underlie the disease. In recent years genome-wide association 102 
studies (GWAS) have made considerable advances in identifying genetic components 103 
underlying complex traits, in many cases identifying novel disease pathways and treatments.2  104 
 105 
Characterizing the genetic component to stroke has been challenging, in part due to clinical 106 
heterogeneity, with at least three distinct major pathological processes (cardioembolism, large 107 
artery atherosclerosis, small vessel disease) underlying the majority of ischaemic strokes; and 108 
two processes underlying the majority of intracerebral haemorrhagic stroke (small vessel 109 
disease and cerebral amyloid angiopathy). 3, 4 However, recent GWAS have made 110 
considerable advances; 32 independent genome-wide significant loci were identified in the 111 
MEGASTROKE project. 5 The majority of these loci were identified as being associated with 112 
inclusive ‘all stroke’ or ‘ischaemic stroke’ categories, rather than specific stroke subtypes. This 113 
is in part due to study design, with much larger samples for these broader categories and only 114 
a fraction of stroke cases having detailed phenotyping. Indeed, this finding is in contrast to 115 
earlier studies that identified loci such as HDAC9, PITX2 as being associated with specific 116 
subtypes. 6, 7 In order to interpret genetic risk associations in the context of biological 117 
mechanisms, a pertinent question is whether the newly identified stroke-associated loci truly 118 
confer risk across all stroke subtypes, or whether isolated or combinations of subtypes are 119 
affected. At least one of the novel variants (on chromosome 1q22) shows association with 120 
both ischaemic and haemorrhagic stroke, which might point to some shared mechanisms 121 
underlying these clinically distinct entities, which have thus far been separated in genetic 122 
studies.  123 
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 124 
Conventional approaches to GWAS, which employ within study analysis and subsequent 125 
meta-analysis across groups, do not enable detailed model comparison across different 126 
subgroups. In this analysis, we used multinomial logistic regression on well-characterized 127 
subjects with individual-level data to investigate the association of all identified genetic GWAS 128 
loci to date with all stroke subtypes (cardioembolic (CES), large artery stroke (LAS), small 129 
vessel stroke (SVS) and intracerebral haemorrhage (ICH)), determining the most likely 130 
combination of stroke subtypes affected at each locus. We performed our analysis using two 131 
established subtyping approaches: the Trial of Org 10172 in Acute Stroke Treatment (TOAST), 132 
8 and Causative Classification of Stroke (CCS) system,9 to provide a comprehensive account 133 
of these loci across available classification systems. Our overall aim was to evaluate genetic 134 
loci identified in previous studies using stroke datasets with well-defined phenotyping to 135 
determine if subtype specificity or cross-subtype associations could be identified. 136 
 137 
Methods 138 
In order to minimize the possibility of unintentionally sharing information that can be used to 139 
re-identify private information, a subset of the data generated for this study are available at 140 
dbGAP and can be accessed at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-141 
bin/study.cgi?study_id=phs000615.v1.p1. 142 
All contributing studies were approved by institutional review committees; subjects gave 143 
informed consent. 144 
Full methods are provided in the Data Supplement. 145 
 146 
Results 147 
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After QC, there were up to 16,664 cases and 32,792 controls remaining for analysis (Table 1). 148 
In the merged dataset, a binomial genome-wide analysis of all cases against controls had a 149 
genomic inflation lambda=1.09, while the LDSCORE intercept value was 1.04, 10 suggesting 150 
that the majority of inflation was due to polygenicity and that any bias introduced by merging 151 
the datasets was minimal.  152 
 153 
Sixteen loci contained SNPs with log(Bayes factors) of at least 4 in analyses of alternative 154 
stroke classification systems: Trial of Org 10172 Acute Stroke Treatment Classification 155 
System (TOAST) or Causative Classification of Stroke System (CCS) (causative system). We 156 
took these sixteen loci forward for further model selection. Plots for all loci under each 157 
classification system are provided in Supplementary Figures 1-16. For each of the sixteen loci, 158 
we identified the most likely combination of associated phenotypes at each locus (Figure 1, 159 
Table 2) based on model selection. A comparison of odds ratios for analysed loci from 160 
MEGASTROKE and the most recent ICH publication with those from our analysis showed 161 
high consistency (r2=0.95, Supplementary Figure 17) despite slightly differing samples. LD 162 
values between our lead and previously published SNPs for the 16 loci in this analysis are 163 
provided in Supplementary Table 1. 164 
 165 
For seven loci, the combination of phenotypes most likely to be influenced by the lead genetic 166 
variant at the loci included both ischaemic and haemorrhagic stroke subtypes. Four of these 167 
are shown in Figure 2. At these four loci: EDNRA, 1q22, MMP12, SH3PXD2A, the ischaemic 168 
subtype included SVS, highlighting shared mechanisms underlying ICH and SVS, likely 169 
through predisposition to cerebral small vessel disease. At the EDNRA locus, the direction of 170 
association for ICH was opposite to that for LAS and SVS, pointing to contrasting influence on 171 
ischaemic and haemorrhagic stroke risk. We explored whether ICH-associated loci were 172 
specific to deep or lobar ICH. As in previous reports, 11, 12 associations at 1q22 and COL4A2 173 
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appear to be specific to deep ICH, with no effect in lobar ICH. For other regions, the evidence 174 
for specificity was more equivocal (Supplementary Table 2). 175 
 176 
For four loci: HDAC9, PITX2, ZFHX3, ANK2, only one phenotype was affected by the lead 177 
variant (Figure 1, Supplementary Figures 10, 13, 16, 5) in the most likely configuration across 178 
all classification systems. Several other loci: 9p21, 12q24, 16q24, FOXF2 were associated 179 
with only one phenotype under particular classification systems, but did not show consistency 180 
across TOAST and CCS (Supplementary Figures 2, 3, 4, 9).  For TSPAN2, which was 181 
previously identified as being associated with LAS, 13 the best-fit model also included CES 182 
under CCS, albeit with a much weaker effect than LAS (rs17479660; CES, OR=1.08; LAS, 183 
OR=1.19 under CCS). Echoing previous results, the locus showed much stronger significance 184 
under CCS classifications than under TOAST (Supplementary Figure 15). 185 
 186 
For COL4A2, the strongest association found under TOAST was for rs9515201. The most 187 
likely model contained ICH (OR=1.14) and SVS (OR=1.13), consistent with findings from 188 
previous analyses. 12 However, under CCS an alternate SNP, rs1927349, was the strongest 189 
associated. No association with SVS was observed, and a weak association with CES was 190 
observed instead. Reasons for this discrepancy between CCS and TOAST are not 191 
immediately clear, but non-overlapping samples between the two classification systems are a 192 
likely factor. 193 
 194 
The mean (SD) number of stroke subtypes affected at each locus were 1.88 (0.89) under 195 
TOAST and 1.69 (0.87) under CCS. Under CCS, the most common combination of affected 196 
subtypes was SVS and ICH (4 loci). 197 
 198 
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Discussion 199 
We performed a large-scale genetic analysis, characterising the effects of established stroke 200 
risk loci with ischaemic and haemorrhagic stroke subtypes in up to 16,664 cases and 32,792 201 
controls. Our main findings are twofold. First, for the vast majority of loci studied, multiple but 202 
never all stroke subtypes were affected at the locus. Only one locus (12q24) was assumed to 203 
influence all ischaemic stroke subtypes. This indicates that although these loci were identified 204 
in analyses of inclusive stroke phenotypes, in the main their effects are specific to particular 205 
combinations of stroke subtypes. The mean number of subtypes affected was 1.88 for TOAST 206 
and 1.69 for CCS classification systems. Notable exceptions were the PITX2 and ZFHX3 loci, 207 
which were associated with cardioembolic stroke most likely through atrial fibrillation (for which 208 
they are well-established loci 14), and HDAC9 which is associated with large vessel stroke. 209 
Under TOAST, the FOXF2 locus was associated solely with SVS. However, under CCS, LAS 210 
was also implicated. For CCS, the 9p21 locus was predicted to influence only LAS. However, 211 
under TOAST, SVS was also implicated. Our analyses suggest that ANK2 confers risk of 212 
stroke predominantly through its influence on ICH. We were unable to identify any loci for 213 
which the most likely model included all stroke phenotypes in the same direction and only one 214 
(12q24) which for which the most likely model included all ischaemic stroke subtypes.  215 
 216 
Secondly, we find evidence that several loci influence both haemorrhagic and ischaemic 217 
stroke. This was evident for seven loci in total (1q22, COL4A2, EDNRA, LINC01492, MMP12, 218 
SH3PXD2A, CDK6). Under CCS, 4 loci (SH3PXD2A, MMP12, EDNRA, 1q22) influenced both 219 
SVS and ICH, highlighting shared mechanisms underlying small vessel disease. Previous 220 
GWAS analyses have tended to separate ischaemic and haemorrhagic stroke on the basis of 221 
presumed differing etiologies. Our results suggest that including haemorrhagic alongside 222 
ischaemic stroke in multiphenotype analyses will provide further insights. 223 
 224 
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For one locus: Endothelin Receptor Type A (EDNRA), the association with ICH was in the 225 
opposite direction to the ischaemic stroke subtypes, suggesting opposing risk mechanisms. 226 
This locus has previously been associated with a variety of vascular phenotypes, including 227 
coronary artery disease, carotid plaques, and peripheral arterial disease (all in concordant 228 
direction with ischaemic stroke), as well as intracranial aneurysm (in concordant direction with 229 
intracerebral haemorrhage). 15-18 The locus has also been associated with migraine in 230 
candidate gene studies, 19 but this has not been validated in GWA studies and is likely a false 231 
positive. 20 EDNRA encodes the type A receptor (ETA) for Endothelin-1 (ET-1), a potent 232 
vasoconstrictor with pro-inflammatory effects. ETA -specific antagonists increase Nitric Oxide 233 
(NO)-mediated endothelium-dependent relaxation, reduce ET-1 levels and inhibit 234 
atherosclerosis in mice, 21 suggesting that higher levels of ETA are pro-atherogenic: consistent 235 
with the observation that higher ETA levels are observed in atherosclerotic plaques. 22 Based 236 
on this, one might expect the EDNRA risk variant (C allele of rs17612742 in this study) to lead 237 
to increased risk of ischaemic stroke through elevated ETA levels. Indeed, in GWA studies of 238 
intracranial aneurysm the susceptibility variant (in LD with the T allele of rs17612742 in our 239 
study) was shown to result in higher transcription factor binding affinity, likely resulting in 240 
repression of the transcriptional activity of EDNRA. 17 This suggests that carries of the C allele 241 
have lower levels of EDNRA, which consequently higher ET-1 levels and greater susceptibility 242 
to atherosclerosis. The reason why for carriers of T allele lower levels of ETA might promote 243 
intracranial aneurysm and intracerebral haemorrhage is not immediately obvious, but several 244 
mechanisms are possible. Levels of ET-1 have been linked to vascular remodelling, an 245 
important process underlying ICH and IA; 23, 24 subtle changes in this process induced by 246 
altered availability of ETA is one such mechanism. Deep ICH and ischaemic SVS arise due to 247 
the same arteriopathy that arises in the deep perforating arteries of the brain. The EDNRA 248 
variant in this study points to a mechanism that influences whether the resulting pathology is 249 
ischaemic or haemorrhagic, and as such warrants further detailed investigation. 250 
 251 
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 252 
Some loci were notably more significant when phenotyped using CCS; SH3XPD2A, MMP12, 253 
TSPAN2, FOXF2, EDNRA, which might point to CCS having greater accuracy and therefore 254 
utility in stroke GWA studies. However, the opposite was also true for others: 16q24, HDAC9. 255 
We note that some differences may be due to the fact that not all individuals were subtyped 256 
under both CCS and TOAST; the TOAST cohort was a least 20% larger.  A detailed discussion 257 
of the relative merits of TOAST and CCS is beyond the scope of this article, but our results 258 
highlight that the importance of collecting individual phenotypic qualities that make up the 259 
etiologic subtypes in genetic studies of stroke so that associated loci can be more 260 
systematically examined. 261 
 262 
Our study has several strengths. The dataset was a large stroke population including 263 
intracerebral haemorrhage and ischaemic stroke cases, the majority of which were subtyped 264 
under both TOAST and CCS. We had full access to genotype-level data enabling us full control 265 
over all analyses. The implementation of a multinomial regression approach enabled us to 266 
systematically assess which stroke subtypes were likely to be affected at each locus, which 267 
would not be formally possible under standard binomial regression approaches which analyse 268 
each stroke subtype separately. Ultimately, mechanistic studies will be required to determine 269 
the influence of associated genetic variants, but analyses such as this have utility in directing 270 
the focus and model systems suitable for such follow up studies. 271 
 272 
Similarly there are limitations. We present results for the most likely combination of stroke 273 
phenotypes affected at each locus: the ‘best-fitting’ model. We had limited statistical power to 274 
determine with statistical certainty that this was the correct model; significantly larger samples 275 
would be required to achieve this. One consequence of this is that there remains the potential 276 
that some associations are due to random variation rather than true biological differences. It 277 
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would therefore be prudent to treat some of the findings here as preliminary until confirmed in 278 
larger samples. Due to the challenges of performing these analyses across different ancestry 279 
populations, and as we only had a small number of non-European ancestry ICH cases 280 
available which could lead to overfitting, we performed analyses in European populations only. 281 
The results can therefore not be generalized to all populations. Repeating these analyses 282 
once sufficient data from other ancestral groups are available should be highly prioritized to 283 
ensure advancements in the field are made for all ancestral groups. In all analyses we assume 284 
there is a single causal variant at the locus, which may not be true in all cases. Our analyses 285 
are based on use of a default prior, which has been used in many genetic studies. An 286 
alternative is to derive an empirical prior from associated genetic loci. As more loci are 287 
identified as being associated with stroke, this will become a more realistic possibility and 288 
should be explored in future analyses. 289 
 290 
Conclusions 291 
Our findings suggest that although large scale genome-wide studies of broad ‘all stroke’ or ‘all 292 
ischaemic stroke’ phenotypes are able to identify multiple associations, it should not be 293 
assumed that such associations confer risk equally across stroke subtypes. Heterogeneity in 294 
the influence of genetic variants on different stroke subtypes is the norm, not the exception. 295 
The multinomial regression approach used here provided insights into the etiological stroke 296 
subtypes most prominently influenced by genetic variants at these loci – a prerequisite to 297 
decide on the most appropriate model systems to choose for further mechanistic studies. 298 
Stroke is a complex, heterogeneous disorder: our findings highlight the ongoing need for large, 299 
well phenotyped case collections and tailored analytic strategies to decipher the underlying 300 
genetic mechanisms.  301 
 302 
 303 
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Tables and Figures 395 
Table 1.  Sample Sizes 396 
 TOAST CCS 
 N Age 
(mean(SD)) 
Male (%) N Age 
(mean(SD)) 
Male (%) 
CES 3847 72(14) 49 2826 75(12) 44 
LAS 2803 68(12) 65 2204 67(12) 62 
SVS 3976 64(13) 62 3093 63(13) 62 
UND 4085 65(16) 54 4013 65(15) 53 
ICH 1953 71(13) 53 1953 71(13) 53 
Controls 32792 62(17) 46 28052 62(17) 48 
 397 
CES, cardioembolic Stroke; LAS, large artery atherosclerotic stroke; SVS, small artery 398 
occlusion stroke; UND, stroke of undetermined etiology; ICH, intracerebral haemorrhage; 399 
TOAST, Trial of Org 10172 Acute Stroke Treatment Classification System; CCS, Causative 400 
Classification of Stroke System (causative system). Age available not available for controls 401 
from WTCCC2 studies. 402 
  403 
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Table 2 – Lead SNPs, Association Statistics, and Affected Stroke Subtypes for Each 404 
Locus 405 
Locus Lead SNP [Best 
Model] 
log OR (SE) log BF Subtypes in 
Best Fitting 
Model 
1q22 rs2758603 [CCS] 0.10 (0.03) SVS 
0.11 (0.05) ICH 
0.02 (0.03) CES 
0.07 (0.03) UNK 
0.07 (0.03) LAS 
4.0 SVS, ICH 
9p21 rs1412830 [TOAST] 0.08 (0.03) SVS 
0.07 (0.04) ICH 
-0.01 (0.03) CES 
0.03 (0.03) UNK 
0.14 (0.03) LAS 
5.7 LAS, SVS 
12q24 rs10774624 [TOAST] 0.10 (0.03) SVS 
-0.03 (0.05) ICH 
0.07 (0.03) CES 
0.07 (0.03) UNK 
0.10 (0.03) LAS 
5.8 CE, LAS, SVS 
16q24 rs12445022 [TOAST] 0.13 (0.03) SVS 
0.05 (0.05) ICH 
-0.01 (0.03) CES 
0.07 (0.03) UNK 
0.07 (0.03) LAS 
5.8 LAS, SVS 
ANK2 rs149538932 [CCS] 0.07 (0.03) SVS 
0.18 (0.05) ICH 
0.04 (0.03) CES 
0.08 (0.03) UNK 
0.02 (0.03) LAS 
6.4 ICH 
CDK6 rs4272 [CCS] 0.05 (0.04) SVS 
0.10 (0.05) ICH 
0.07 (0.03) CES 
0.12 (0.03) UNK 
0.14 (0.04) LAS 
8.5 LAS, ICH 
COL4A2 rs1927349 [CCS] -0.02 (0.03) SVS 
0.16 (0.05) ICH 
0.08 (0.03) CES 
0.04 (0.03) UNK 
0.02 (0.03) LAS 
5.0 CES, ICH 
EDNRA rs17612742 [CCS] 0.09 (0.04) SVS 
-0.23 (0.06) ICH 
-0.08 (0.04) CES 
-0.00 (0.04) UNK 
0.13 (0.04) LAS 
10.5 CES, LAS, SVS, 
ICH 
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FOXF2 rs11242678 [CCS] 0.13 (0.03) SVS 
-0.05 (0.05) ICH 
0.07 (0.03) CES 
0.09 (0.03) UNK 
0.09 (0.04) LAS 
7.4 LAS, SVS 
HDAC9 rs2107595 [TOAST] 0.04 (0.04) SVS 
-0.08 (0.06) ICH 
0.05 (0.04) CES 
0.06 (0.03) UNK 
0.27 (0.04) LAS 
19.2 LAS 
LINC01492 rs10990643 [TOAST] -0.02 (0.04) SVS 
0.12 (0.06) ICH 
0.03 (0.04) CES 
0.01 (0.03) UNK 
0.17 (0.04) LAS 
4.1 LAS, ICH 
MMP12 rs470234 [CCS] 0.09 (0.04) SVS 
0.17 (0.06) ICH 
0.04 (0.04) CES 
0.03 (0.04) UNK 
0.20 (0.04) LAS 
8.7 LAS, SVS, ICH 
PITX2 rs2723334 [TOAST] 0.0 (0.04) SVS 
0.08 (0.06) ICH 
0.29 (0.04) CES 
0.03 (0.03) UNK 
-0.03 (0.04) LAS 
48.0 CES 
SH3PXD2A rs10883922 [CCS] 0.13 (0.03) SVS 
0.16 (0.05) ICH 
0.02 (0.03) CES 
0.02 (0.03) UNK 
0.04 (0.03) LAS 
6.0 SVS, ICH 
TSPAN2 rs7537796 [CCS] -0.05 (0.03) SVS 
-0.06 (0.05) ICH 
0.06 (0.03) CES 
-0.02 (0.03) UNK 
0.14 (0.03) LAS 
6.8 CES, LAS 
ZFHX3 rs67329386 [TOAST] -0.02 (0.03) SVS 
-0.05 (0.05) ICH 
0.20 (0.03) CES 
0.02 (0.03) UNK 
0.00 (0.03) LAS 
13.8 CES 
CES, Cardioembolic Stroke; LAS, Large artery Stroke; SVS, Small Vessel Stroke; ICH, 406 
Intracerebral Haemorrhage; log BF, log transform of Bayes Factor; log OR, log transform of 407 
Odds Ratio; SE, standard error; CCS, causative classification system of stroke; TOAST, Trial 408 
of Org 10172 Acute Stroke Treatment Classification System  409 
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Figure 1.  Stroke Subtypes in Best Fitting Model at Each Locus, for CCSc, CCSp, and TOAST 410 
classification Systems, with Size Weighted by Association Odds Ratio 411 
 412 
CES, Cardioembolic Stroke; LAS, Large artery Stroke; SVS, Small Vessel Stroke; ICH, 413 
Intracerebral Haemorrhage. Results are presented for the 16 loci showing log(Bayes 414 
Factor)>4 in CCS or TOAST analyses. Classification/Locus combinations in grey indicate that 415 
the locus did not reach log(Bayes Factor)>4 in that analysis.  416 
  417 
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Figure 2.  Local Plots showing Associations with Regions Conferring Risk of Ischaemic and 418 
Haemorrhagic Stroke and Odds Ratios for all stroke Subtypes 419 
 420 
A, 1q22 region; B, EDNRA region; C, CDK6 region; D, LINC01492 region; E, SH3PXD2A 421 
region; F, MMP12 region; G, COL4A2 region; CE, cardioembolic stroke; LAS, large artery 422 
atherosclerotic stroke; SVS, small vessel stroke; ICH, intracerebral haemorrhage. Results are 423 
presented for the classification system in which the locus showed strongest significance. 424 
Stroke subtypes in bold indicate those included in the best fitting model and therefore 425 
predicted to be influenced by the lead genetic variant, based on Bayesian model selection. 426 
